BioLineRx Reports Engraftment Data of BL-8040 in P-III GENESIS Trial for Patients with Multiple Myeloma

 BioLineRx Reports Engraftment Data of BL-8040 in P-III GENESIS Trial for Patients with Multiple Myeloma

BioLineRx Reports Engraftment Data of BL-8040 in P-III GENESIS Trial for Patients with Multiple Myeloma

Shots:

  • The P-III GENESIS Trial involves assessing of BL-8040 + G-CSF (granulocyte colony-stimulating factor) vs G-CSF/PBO in 177 patients with multiple myeloma for the mobilization of CD34 HSCs for autologous transplantation across 25 centres
  • The study resulted in meeting 1EP with 82% patients reached threshold ≥ 6×106 CD34 cells/kg in 2 apheresis sessions, 64% reached threshold ≥ 6×106 CD34 cells/kg in single apheresis, successful engraftment with BL-8040 mobilized HSCs was observed
  • BL-8040 is a cancer therapy leading to mobilization of HSCs into the peripheral blood targeted for the treatment of hematological malignancies and solid tumors. BioLineRx in-licensed BL-8040 from Biokine Therapeutics and was developed with the name BKT-140

Click here to read full press release/ article | Ref: BiolineRx | Image: WJH

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post